MAM
CRDF icon

Meeder Asset Management’s Cardiff Oncology CRDF Stock Holding History

Meeder Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-376
Closed -$1.74K – 1570
2018
Q2 		$1.74K Buy
376
+301
+401% +$5.03K ﹤0.01% 1435
2018
Q1 		$2K Hold
75
– – ﹤0.01% 1370
2017
Q4 		$2K Buy
75
+39
+108% +$1.73K ﹤0.01% 1483
2017
Q3 		$2K Buy
36
+14
+64% +$873 ﹤0.01% 1443
2017
Q2 		$2K Buy
22
+7
+47% +$451 ﹤0.01% 1391
2017
Q1 		$1K Sell
15
-71
-83% -$9.64K ﹤0.01% 1497
2016
Q4 		$13K Buy
+86
New +$20.1K ﹤0.01% 708

Other funds holding CRDF

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return
DY
Dowling & Yahnke San Diego, California $2.15B AUM 10.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SNB
Security National Bank Omaha, Nebraska $838M AUM 39.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Meeder Asset Management's CRDF Position: Q3 2018 in Review

Meeder Asset Management sold out of Cardiff Oncology (CRDF) in Q3 2018, closing a stake of 376 shares — an estimated $1.74K sold.

Meeder Asset Management first reported a position in CRDF in Q4 2016 and held it in 7 quarters. The position peaked at $13K in Q4 2016. 33 funds tracked by Wall St. Rank hold CRDF as of Q3 2018.

  • Meeder Asset Management reported no remaining Cardiff Oncology position as of Q3 2018 after selling out during the quarter.
  • Meeder Asset Management sold 376 Cardiff Oncology shares in Q3 2018, an estimated $1.74K.
  • Meeder Asset Management first reported a position in Cardiff Oncology in Q4 2016 and held it in 7 quarters.
  • Meeder Asset Management's Cardiff Oncology position peaked at $13K in Q4 2016.
  • 33 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.